EFARMZ is a shop in Anderlecht. Private Limited, started on 28 May 2013, 1 establishment.

What is the address of EFARMZ?

The registered office of EFARMZ is located at Industrielaan 135, 1070 Anderlecht.

Is EFARMZ still active?

Yes. According to the CBE (28 September 2026) EFARMZ is active, legal situation “Normale toestand”, started on 28 May 2013.

Is EFARMZ registered on Peppol?

Yes, EFARMZ is registered on the Peppol network with ID 0208:0534744073.

What is the enterprise number of EFARMZ?

The enterprise number of EFARMZ is BE0534744073.

When was EFARMZ founded?

EFARMZ was founded on 28 May 2013.

Is EFARMZ a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 28 May 2013; 5 annual accounts filed, latest fiscal year 2025; 7 directors known from the annual account.

How much profit did EFARMZ make in 2025?

EFARMZ recorded a loss after taxes of € 567,233 in financial year 2025.

What is the revenue of EFARMZ?

As a small company, EFARMZ is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 2,123,578.

How much does an employee at EFARMZ earn?

The average wage cost per full-time employee at EFARMZ was € 46,700 in 2025: staff costs of € 2.1 million for 45.7 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does EFARMZ have?

According to the 2025 annual accounts, EFARMZ has 45.7 full-time equivalents (FTE).

EFARMZ (Private Limited) - Anderlecht - BE0534744073

Q: Who are the directors of EFARMZ?

According to the 2025 annual accounts, the directors of EFARMZ are: CDP Invest, Philippe Boyens, MB Marketing SRL, AKILES MANAGEMENT, AMS Equity, AKILES SRL, FIDOUNA.

Dossier EFARMZ, printed on 28 September 2026 from databakkes.be/en/0534744073/efarmz. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Negative equity NBB

More debt than assets in 2 of the last 4 fiscal years.
Two loss years in a row NBB

Negative result in 2024 and 2025.
Tight liquidity NBB

Cash and receivables cover 47 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

EFARMZ from Anderlecht, company number BE0534744073, closed financial year 2025 with a result of € -567,233 after tax. For that financial year EFARMZ recorded a gross margin of € 2.1 million and equity of € -40,700. Compared with financial year 2024, the result moved from € -1.1 million to € -567,233. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on May 28, 2026.

What it is worth Caution

€ -40,700

▲ € 27,487 vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -567,233

▲ 49 % less loss than in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 304,158

▲ € 238,849 vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € -4.8 million.

People and assets in 2025

Full-time equivalents

45.7

▲ 3.4 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 2.1 million

▲ 4% vs 2024

€ 46,700 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 62,028

▼ 30% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 6 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 1 million

▼ 9% vs 2024

€ 163,378 is repaid this year. At this pace the long-term loan is gone in ≈ 6 years.

Owed to suppliers

€ 661,106

▼ 2% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 267,494

▲ 40% vs 2024

Taxes, VAT and social contributions still to pay.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 1,535,475 Gross margin 2022: € 1,535,475 First fiscal year in the series	€ 1,365,836 Gross margin 2023: € 1,365,836 ▼ 11% vs 2022 (€ 1,535,475) Unfavourable step	€ 1,507,848 Gross margin 2024: € 1,507,848 ▲ 10% vs 2023 (€ 1,365,836) Favourable step	€ 2,123,578 Gross margin 2025: € 2,123,578 ▲ 41% vs 2024 (€ 1,507,848) Favourable step	▲ 41%
Profit after taxes	€ -840,345 Profit after taxes 2022: € -840,345 First fiscal year in the series	€ -1,428,338 Profit after taxes 2023: € -1,428,338 ▼ € 587,993 vs 2022 (€ -840,345) Unfavourable step	€ -1,107,346 Profit after taxes 2024: € -1,107,346 ▲ € 320,991 vs 2023 (€ -1,428,338) Favourable step	€ -567,233 Profit after taxes 2025: € -567,233 ▲ € 540,114 vs 2024 (€ -1,107,346) Favourable step	▲ € 540,114
Equity	€ 2,467,497 Equity 2022: € 2,467,497 First fiscal year in the series	€ 1,039,160 Equity 2023: € 1,039,160 ▼ 58% vs 2022 (€ 2,467,497) Unfavourable step	€ -68,187 Equity 2024: € -68,187 ▼ € 1.1 million vs 2023 (€ 1,039,160) Unfavourable step	€ -40,700 Equity 2025: € -40,700 ▲ € 27,487 vs 2024 (€ -68,187) Favourable step	▲ € 27,487
Total debts	€ 1,164,212 Total debts 2022: € 1,164,212 First fiscal year in the series	€ 1,245,226 Total debts 2023: € 1,245,226 ▲ 7% vs 2022 (€ 1,164,212) Unfavourable step	€ 2,062,020 Total debts 2024: € 2,062,020 ▲ 66% vs 2023 (€ 1,245,226) Unfavourable step	€ 1,991,705 Total debts 2025: € 1,991,705 ▼ 3% vs 2024 (€ 2,062,020) Favourable step	▼ 3%
Cash	€ 2,061,980 Cash 2022: € 2,061,980 First fiscal year in the series	€ 177,785 Cash 2023: € 177,785 ▼ 91% vs 2022 (€ 2,061,980) Unfavourable step	€ 65,309 Cash 2024: € 65,309 ▼ 63% vs 2023 (€ 177,785) Unfavourable step	€ 304,158 Cash 2025: € 304,158 ▲ € 238,849 vs 2024 (€ 65,309) Favourable step	▲ € 238,849
Retained profit	€ -1,676,451 Retained profit 2022: € -1,676,451 First fiscal year in the series	€ -3,104,789 Retained profit 2023: € -3,104,789 ▼ € 1.4 million vs 2022 (€ -1,676,451) Unfavourable step	€ -4,212,135 Retained profit 2024: € -4,212,135 ▼ € 1.1 million vs 2023 (€ -3,104,789) Unfavourable step	€ -4,779,368 Retained profit 2025: € -4,779,368 ▼ € 567,233 vs 2024 (€ -4,212,135) Unfavourable step	▼ € 567,233
Bank debt	€ 207,444 Bank debt 2022: € 207,444 First fiscal year in the series	€ 158,673 Bank debt 2023: € 158,673 ▼ 24% vs 2022 (€ 207,444) Favourable step	€ 1,119,746 Bank debt 2024: € 1,119,746 ▲ € 961,074 vs 2023 (€ 158,673) Unfavourable step	€ 1,018,224 Bank debt 2025: € 1,018,224 ▼ 9% vs 2024 (€ 1,119,746) Favourable step	▼ 9%
Balance sheet total	€ 3,631,709 Balance sheet total 2022: € 3,631,709 First fiscal year in the series	€ 2,284,386 Balance sheet total 2023: € 2,284,386 ▼ 37% vs 2022 (€ 3,631,709) Unchanged	€ 1,993,834 Balance sheet total 2024: € 1,993,834 ▼ 13% vs 2023 (€ 2,284,386) Unchanged	€ 1,951,004 Balance sheet total 2025: € 1,951,004 ▼ 2% vs 2024 (€ 1,993,834) Unchanged	▼ 2%
Employees (FTE)	46 Employees (FTE) 2022: 46 First fiscal year in the series	49.5 Employees (FTE) 2023: 49.5 ▲ 3.5 vs 2022 (46) Unchanged	42.3 Employees (FTE) 2024: 42.3 ▼ 7.2 vs 2023 (49.5) Unchanged	45.7 Employees (FTE) 2025: 45.7 ▲ 3.4 vs 2024 (42.3) Unchanged	▲ 3.4

Key figures of EFARMZ, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to EFARMZ?

What happened at EFARMZ in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

May 28, 2026 New annual accounts for financial year 2025: loss of € 567,233. Source: NBB ↗
2025 Philippe Boyens became a director. NBB
2023 CDP Invest became a director. NBB
2022 MB Marketing SRL became a director. NBB
2022 AKILES MANAGEMENT became a director. NBB
2022 AMS Equity became a director. NBB
2022 AKILES SRL became a director. NBB
2022 FIDOUNA became a director. NBB

In short

From € 840,345 loss in 2022 to € 567,233 loss in 2025.

On average € 46,500 of value added per employee in 2025.

Original PDFs at the National Bank ↗

A new publication or filing at EFARMZ? We notify you, reason included.

Follow EFARMZ

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

AKILES 40.9%

FIDOUNA 24.9%

The stake of AKILES, FIDOUNA comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

EFARMZ

Behind EFARMZ are CDP Invest, Philippe Boyens, MB Marketing SRL, AKILES MANAGEMENT, AMS Equity and AKILES SRL. The shares are held by AKILES (40.9%) and FIDOUNA (24.9%).

See the full network in the app